TVMR With the Innovalve System Trial - Pilot Study in Italy (TWIST-PILOT-IT)

Study to evaluate the safety and performance of the Innovalve mitral valve replacement system

Study Overview

• Status: Active, not recruiting
• Conditions: Mitral Valve Regurgitation (Degenerative or Functional)
• Intervention / Treatment: Device: Innovalve TMVR system

• Study Type: Interventional
• Enrollment (Actual): 4
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Italy
  • Milan, Italy
    • Humanitas

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Clinically significant, symptomatic mitral regurgitation
• High risk for open-heart surgery
• Meets anatomical criteria

Exclusion Criteria:

• Unsuitable anatomy
• Patient is inoperable
• EF <30%

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: MV replacement with Innovalve MR system	Device: Innovalve TMVR system; Innovalve TMVR system

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Absence of implant or delivery related serious adverse events at 30 days	Absence of implant or delivery related serious adverse events at 30 days	30 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Technical Success	All of the following must be present: i. Absence of procedural mortality; and ii. Successful access, delivery, and retrieval of the device delivery system; and iii. Successful deployment and correct positioning of the first intended device; and iv. Freedom from emergency surgery or reintervention related to the device or access procedure.	Procedure
Procedural Success	All of the following must be present: I. Deployment of the device II. Absence of major device- or procedure-related SAEs, including: Death; Stroke; Life-threatening bleeding (Mitral Valve Academic Research Consortium [MVARC] definition); Major vascular complications requiring surgery to repair; Major cardiac structural complications requiring surgery to repair; Stage 2 or 3 acute kidney injury (including new dialysis); Myocardial infarction or coronary ischemia requiring percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG); Unexpected cardiogenic shock requiring intensive care unit (ICU) admission and treatments such as ultrafiltration or hemodynamic assist devices, including intra-aortic balloon pumps or left ventricular (LV) or biventricular assist device, or prolonged intubation for > 48 hours.; Any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention	30 days
Device Success	All of the following must be present: Absence of procedural mortality or stroke; and; Proper placement and positioning of the device; and; Freedom from unplanned surgical or interventional procedures related to the device or access procedure; and; Continued intended safety and performance of the device, including:; No evidence of major structural or functional failure; No specific, major device-related technical failure issues and complications; Reduction of MR to either optimal or acceptable levels* without significant mitral stenosis (i.e., post-procedure effective orifice area [EROA] ≥ 1.5 cm2 with transmitral mean gradient < 5 mmHg), no greater than mild (1+) paravalvular leak (PVL), and no hemolysis	30 days, 3, 6, 12 months and annually up to 5 years
Patient Success	All of the following must be present: Deployment of the device; Patient returned to the pre-procedural setting; and; No rehospitalizations or reinterventions for the underlying condition (e.g., MR, heart failure); and; Improvement from baseline in symptoms (e.g., New York Heart Association [NYHA] Class improvement by ≥ 1 class); and; Improvement from baseline in functional status (e.g., 6-minute walk test/distance [6MWT/D] improvement by ≥ 50 m); and; Improvement from baseline in quality-of-life (e.g., Kansas City Cardiomyopathy Questionnaire [KCCQ-12] improvement by ≥ 10 points)	1 year
Increase in 6MWD		from baseline to 30 days, 3, 6, 12 months and annually up to 5 years
Reduction in MR grade		from baseline to 30 days, 3, 6, 12 months and annually up to 5 years
Atrial septal defects requiring closure		30 days, 3, 6, 12 months and annually up to 5 years
Change in NYHA Class	New York Heart Association (NYHA) functional classification of heart failure is based on how much a patient is limited during physical activity. The rating ranges from Class I-IV. Class I = no limitations of physical activity; Class II = slight limitations of physical activity, ordinary physical activity results in fatigue, palpitation, shortness of breath; Class III = marked limitations of physical activity, less than ordinary activity causes fatigue, palpitation, or shortness of breath; Class IV = unable to carry on any physical activity without discomfort, symptoms of heart failure at rest.	30 days, 3, 6, 12 months and annually up to 5 years
Quality of life change (KCCQ-12)	The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. An overall summary score can be derived from the physical function, symptom (frequency and severity), social function, and quality of life domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.	from baseline to 30 days, 3, 6, 12 months and annually up to 5 years
Change in Montreal Cognitive Assessment (MoCa)	The Montreal Cognitive Assessment is a 30-point test assessing multiple cognitive domains, including short-term memory recall, visuospatial abilities, executive function, attention, concentration, working memory, language, and orientation to time and place. Scores are on a 30-point scale; scores 26 and above indicate normal cognitive function. Lower scores may indicate mild cognitive impairment (scores 19-25), moderate impairment (scores 10-18), or severe impairment (scores less than 10).	Discharge and 30 days
Composite of MVARC criteria	Number of patients who experience composite endpoint events: death due to any cause, repeat hospitalization due to heart failure, disabling stroke, myocardial infarction, life-threatening major bleeding, acute kidney injury, or specific device-related major technical failure issues and complications. b. Repeat hospitalization for heart failure c. Disabling stroke d. Myocardial infarction e. Life-threatening major bleeding f. Acute kidney injury g. Specific device-related major technical failure issues and complications	30 days, 3, 6, 12 months and annually up to 5 years

Collaborators and Investigators

• Sponsor: Edwards Lifesciences
• Investigators: Principal Investigator: Antonio Colombo, Prof, Humanitas IRCCS

Study record dates

Study Major Dates

• Study Start (Actual): January 24, 2023
• Primary Completion (Actual): May 4, 2024
• Study Completion (Estimated): October 4, 2029

Study Registration Dates

• First Submitted: August 11, 2021
• First Submitted That Met QC Criteria: August 11, 2021
• First Posted (Actual): August 18, 2021

Study Record Updates

• Last Update Posted (Actual): June 26, 2025
• Last Update Submitted That Met QC Criteria: June 23, 2025
• Last Verified: June 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Heart Diseases; Heart Valve Diseases; Mitral Valve Insufficiency
• Other Study ID Numbers: INVL20-01-IT

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No